Dianthus Therapeutics, Inc. cash flow to debt ratio of -9.31K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Dianthus Therapeutics, Inc.'s free cash flow has decreased 65.13% from $-78.28M last year to $-129.27M, signaling decreasing performance

Dianthus Therapeutics, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Dianthus Therapeutics, Inc.'s debt has decreased relative to shareholder equity from 0.00 last year to 0.00 today, signaling strengthened financials

Dianthus Therapeutics, Inc. has a net cash position, so leverage is healthy.

Dianthus Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Dianthus Therapeutics, Inc.'s profit margin has decreased (15.27%) in the last year from -1.36K% to -1.57K%, signaling decreasing performance

Dianthus Therapeutics, Inc.'s short-term assets of $409.44M exceed its short-term liabilities of $30.73M

Dianthus Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Dianthus Therapeutics, Inc.'s return on equity of -3.51%, is lower than 15.00%, indicating bad performance

Dianthus Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Dianthus Therapeutics, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Dianthus Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Dianthus Therapeutics, Inc. has negative free cash flow, indicating cash burn

Dianthus Therapeutics, Inc.'s yearly earnings has decreased 91.05% since last year from $-84.97M to $-162.34M, signaling decreasing performance

Dianthus Therapeutics, Inc.'s yearly revenue has decreased 67.35% since last year from $6.24M to $2.04M, signaling decreasing performance

ROIC -18.47% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Dianthus Therapeutics, Inc.'s 3-year revenue CAGR of -31.80% is negative, indicating declining revenue over the past 3 years

Dianthus Therapeutics, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Dianthus Therapeutics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Dianthus Therapeutics, Inc. has insufficient data to evaluate this check.

Dianthus Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Dianthus Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Dianthus Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Dianthus Therapeutics, Inc. has insufficient data to evaluate this check.

Dianthus Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Dianthus Therapeutics, Inc. has a price-to-book ratio of 5.34x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Dianthus Therapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue